Alvotech Eyes $450m Funding And Public Listing With SPAC Merger
Proposed Combination Would Have Initial Enterprise Value Of Around $2.25bn
Eight years after its inception, pure-play biosimilars company Alvotech has announced plans to list on the NASDAQ via a SPAC merger that will deliver hundreds of millions in cash to fund product development and future growth.
